Sign in
← Database
Adenosine A2A Receptor Antagonist

KW-6356

Shop · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

An investigational adenosine A2A receptor antagonist studied in the context of Parkinson's disease; it is clinical-stage, but its therapeutic profile is not fully established.

How it works

KW-6356 is an investigational small-molecule drug that acts on the adenosine A2A receptor, a target of interest in Parkinson's disease. A2A receptors are concentrated in brain regions involved in movement control, and blocking them is a strategy aimed at improving motor symptoms, potentially as an alternative or complement to dopamine-based therapies. KW-6356 has been studied as a candidate within this class, which also includes the approved A2A antagonist istradefylline.

Because it is a clinical-stage investigational compound, KW-6356 has been examined in human research, but its full efficacy and safety profile have not been definitively established, and it is not an approved medicine. The broader rationale for A2A antagonists in Parkinson's is reasonably well developed, since the existence of an approved agent in the same class demonstrates that the mechanism can be relevant to motor symptoms. Whether KW-6356 specifically offers meaningful advantages remains a research question.

The accurate framing is that KW-6356 is an investigational adenosine A2A antagonist whose place in Parkinson's treatment, if any, is still being determined. It is not approved for general human use, and claims about its benefits should be regarded as hypotheses under clinical investigation rather than settled conclusions. Its mechanism is reasonably well defined even though its clinical value is not yet proven.

Mechanism · Detailed Analysis
Molecular targetKW-6356 is described as an antagonist of the adenosine A2A receptor, a G-protein-coupled receptor enriched in the basal ganglia. By blocking A2A receptors, the compound is intended to modulate the indirect pathway of motor control. Some reports also discuss A2A inverse agonist activity, but the central described action is A2A antagonism.
Signaling & downstream effectsAdenosine A2A receptors interact functionally with dopaminergic signaling in motor circuits, and antagonizing them is proposed to relieve the dampening influence on movement that contributes to Parkinsonian symptoms. This mechanism underlies the broader interest in A2A antagonists as non-dopaminergic adjuncts. The precise clinical consequences for KW-6356 are still being characterized.
Evidence baseEvidence is from preclinical research and clinical-stage human studies of Parkinson's disease; the compound is investigational and its efficacy and safety are not fully established. Specific trial results are not asserted here, and the existence of a related approved drug in the same class does not establish KW-6356's own clinical profile.
CaveatsNot approved for human use as a marketed medicine. Its clinical efficacy and long-term safety remain unproven, the class-level rationale does not guarantee benefit for this specific compound, and no dosing or therapeutic guidance is implied.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.